[
    "of the present invention comprises the following aspects:\n1. A dihydroorotate-dehydrogenase inhibitor for use in the treatment or amelioration of a disease or medical condition caused by a viral infection by double stranded DNA viruses (dsDNA viruses), positive-sense single-stranded RNA viruses ((+)ssRNA viruses), negative-sense single-stranded RNA viruses ((\u2212)ssRNA viruses), double-stranded DNA viruses (dsDNA), single-stranded RNA viruses which use a DNA intermediate to replicate (ssRNA-RT viruses), double-stranded DNA viruses which use an RNA intermediate during genome replication (dsDNA-RT viruses), wherein the dihydroorotate-dehydrogenase inhibitor is not leflunomide or a metabolite thereof.2. A dihydroorotate-dehydrogenase inhibitor according to aspect 1 for use in the treatment or amelioration of a disease or medical condition caused by a viral infection by a virus selected from the group comprising Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Influenza, BK-Polyomavirus (BKV), Human Cytomegaly Virus (HCMV), Rift Valley Fever *Virus (RVFV), Norovirus (NV), Lassa Virus (LV), Ebolavirus (EBOV), West Nile Virus (WNV), Dengue Virus (DV), Human Respiratory Syncytial Virus (RSV), Yellow fever virus (YFV).3. A dihydroorotate-dehydrogenase inhibitor for use in the treatment or amelioration of a disease or medical condition caused by a viral infection according to aspect 1 or 2, wherein the dihydroorotate-dehydrogenase inhibitor has a half-maximal inhibitory concentration (IC<sub>50</sub>) of 50 nM or less for the inhibition of dihydroorotate-dehydrogenase or less in an in vitro assay and a half-maximal effective concentration (EC<sub>50</sub>) of 200 nM or less for inhibition of viruses in an in vitro assay.4. A dihydroorotate-dehydrogenase inhibitor for use in the treatment or amelioration of a disease or medical condition caused by a viral infection according to any of aspects 1 to 3, wherein the dihydroorotate-dehydrogenase inhibitor has a solubility in water of 10 \u03bcg/mL or greater and/or an absolute oral availability (F) of 30% or greater.5. A dihydroorotate-dehydrogenase inhibitor for use in the treatment or amelioration of a disease or medical condition caused by a viral infection according to any of aspects 1 to 4, wherein the dihydroorotate-dehydrogenase inhibitor is a compound of the general formula (I) or a physiologically functional derivative or a pharmacologically tolerable salt thereof,\n</p><img id=\"EMI-C00002\" path=\"US08354433-20130115-C00002.TIF\" file=\"https://surechembl.org/api/assets/attachment/216048567/US/20130115/B2/000008/35/44/33/US08354433-20130115-C00002.TIF\"/>whereinA is an aromatic or non-aromatic 5- or 6-membered hydrocarbon ring wherein optionally one or more of the carbon atoms are replaced by a group X, wherein X is independently selected from the group consisting of S, O, N, NR<sup>4</sup>, SO<sub>2 </sub>and SO;L is a single bond or NHD is O, S, SO<sub>2</sub>, NR<sup>4</sup>, or CH<sub>2</sub>;Z<sup>1 </sup>is O, S, or NR<sup>5</sup>;Z<sup>2 </sup>is O, S, or NR<sup>5</sup>;R<sup>1 </sup>independently represents H, halogen, hal",
    "asonable fashion to furnish further specific embodiments.</p>Due to their favourable pharmacokinetic properties, the compounds of the present invention are suited for oral treatment regimen wherein the medicament comprising the compound according to the present invention is administered once daily.</p>In one embodiment, the compounds of the present invention are for the treatment or amelioration of a disease or medical condition caused by HIV.</p>In one embodiment, the compounds of the present invention are for the treatment or amelioration of a disease or medical condition caused by HBV.</p>In one embodiment, the compounds of the present invention are for the treatment or amelioration of a disease or medical condition caused by HCV.</p>In one embodiment, the compounds of the present invention are for the treatment or amelioration of a disease or medical condition caused by HPMV.</p>In one embodiment, the compounds of the present invention are for the prevention of transplant rejection due to viral infections, e.g. the rejection of liver transplants due to HCMV, HBV or HCV infection.</p>In one embodiment, the compounds of the present invention are for the treatment of patients co-infected with multiple viruses, e.g. co-infected with HIV/HBV or HIV/HCV.</p>In one embodiment, the compounds of the present invention are applied in combination therapy with interferones, such as interferone \u03b1 or pegylated interferon \u03b1.</p>Preferably, the compounds according to the invention have a half-maximal inhibitory concentration (IC<sub>50</sub>) of 1 \u03bcM or less, more preferably 200 nM or less, and even more preferably 20 nM or less for the inhibition of dihydroorotate-dehydrogenase in an in vitro assay and a half-maximal effective concentration (EC<sub>50</sub>) of 10 \u03bcM or less, preferably 1 \u03bcM or less and even more preferably 200 nM or less for inhibition of viruses in an in vitro assay.</p>Preferably, the compounds according to the invention have a solubility in water of 5 \u03bcg or greater, preferably 10 \u03bcg/mL or greater and/or an absolute oral availability (F) of 10% or greater, more preferably 30% or greater.</p>The compounds according to the present invention are not antimetabolites, and show significantly lower toxic effects on cells compared with antimetabolites.</p>Preferably, the compounds according to the invention exhibit a high solubility in polar, protic solvents, such as in water (solubility (&gt;10 \u03bcg/ml H<sub>2</sub>O)) and/or their oral availability (F) is &gt;30%. Moreover, preferably the compounds of the present invention are chemically stable and the manufacture thereof is inexpensive and straight forward. Accordingly, manufacture of the compounds of the present invention is cost effective.</p>Due to the mode of action of the compounds of the present invention, which involves the interaction with a host-cell based target, the generation of resistant viral strains is unlikely.</p>The following are examples of the compounds according to the present invention.</p>CompoundStructureUPAC name1<img id=\"EMI-C00014\" path=\"US08354433-20130115-C00014.TIF\" file=\"https://surechembl.org/api/assets/attachment/216048500/US/20130115/B2/000008/35/44/33/US08354433-20130115-C00014."
]